In fact, activating ERRγ expression by a specific agonist, DY131, inhibits gastric cancer cell growth and improved patient prognosis.96 Furthermore, ERRγ was described as an anti-proliferative target in androgen-sensitive and androgen-insensitive prostate cancer cells.97 Conversely, ERRγ is up-regulated in liver cancer and its inhibition suppresses cancer cell survival through the p21 and p27 proteins.98 Here, ESRRG is linked to prostate carcinoma.